[go: up one dir, main page]

MX2017001285A - Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos. - Google Patents

Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.

Info

Publication number
MX2017001285A
MX2017001285A MX2017001285A MX2017001285A MX2017001285A MX 2017001285 A MX2017001285 A MX 2017001285A MX 2017001285 A MX2017001285 A MX 2017001285A MX 2017001285 A MX2017001285 A MX 2017001285A MX 2017001285 A MX2017001285 A MX 2017001285A
Authority
MX
Mexico
Prior art keywords
htt
huntingtin
human
antibodies
derived anti
Prior art date
Application number
MX2017001285A
Other languages
English (en)
Other versions
MX391037B (es
Inventor
Grimm Jan
Maier Marcel
Original Assignee
Neurimmune Holding Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurimmune Holding Ag filed Critical Neurimmune Holding Ag
Publication of MX2017001285A publication Critical patent/MX2017001285A/es
Publication of MX391037B publication Critical patent/MX391037B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)

Abstract

Se proporcionan novedosos anticuerpos anti-huntingtina (HTT) derivados de humano y los derivados biotecnológicos de los mismos, de preferencia capaces de enlazarse a las especies mutadas y/o aglomeradas de huntingtina (HTT), y/o los fragmentos de los mismos, así como los métodos relacionados con los mismos. Los anticuerpos anti-huntingtina (HTT) derivados de humano y los derivados biotecnológicos se pueden utilizar en composiciones farmacéuticas y de diagnóstico para la inmunoterapia de la enfermedad de Huntington dirigida a la huntingtina (HTT), y para el diagnóstico de la misma.
MX2017001285A 2014-07-29 2015-07-29 Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos. MX391037B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14179004 2014-07-29
PCT/EP2015/067327 WO2016016278A2 (en) 2014-07-29 2015-07-29 Human-derived anti-huntingtin (htt) antibodies and uses thereof

Publications (2)

Publication Number Publication Date
MX2017001285A true MX2017001285A (es) 2017-04-25
MX391037B MX391037B (es) 2025-03-21

Family

ID=51225442

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017001285A MX391037B (es) 2014-07-29 2015-07-29 Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.
MX2022003704A MX2022003704A (es) 2014-07-29 2017-01-27 Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.
MX2022003706A MX2022003706A (es) 2014-07-29 2017-01-27 Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2022003704A MX2022003704A (es) 2014-07-29 2017-01-27 Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.
MX2022003706A MX2022003706A (es) 2014-07-29 2017-01-27 Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.

Country Status (11)

Country Link
US (3) US10556946B2 (es)
EP (2) EP3174898A2 (es)
JP (3) JP2017522886A (es)
KR (1) KR102643395B1 (es)
CN (2) CN113651887A (es)
AU (3) AU2015295441B2 (es)
CA (1) CA2954738A1 (es)
EA (1) EA201790165A1 (es)
IL (2) IL250180A0 (es)
MX (3) MX391037B (es)
WO (1) WO2016016278A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
EA201790165A1 (ru) * 2014-07-29 2017-07-31 Нейриммьюн Холдинг Аг Происходящие от человека антитела к гентингтину (htt) и их применение
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CA3073066A1 (en) 2017-08-22 2019-02-28 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
US11851487B2 (en) * 2019-04-01 2023-12-26 Rensselaer Polytechnic Institute Methods and systems for detecting peptide aggregates
TW202110878A (zh) 2019-05-16 2021-03-16 法商賽諾菲公司 在神經系統中表現抗原結合蛋白
WO2021071830A1 (en) 2019-10-07 2021-04-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
EP4093426A1 (en) 2020-01-24 2022-11-30 University of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
TW202216760A (zh) 2020-07-23 2022-05-01 愛爾蘭商歐薩爾普羅席納有限公司 抗類澱粉β (ABETA)抗體
CN111909265B (zh) * 2020-08-25 2022-02-11 中国人民解放军军事科学院军事医学研究院 一种结合破伤风毒素重链c端结构域的人源抗体及应用
KR102549520B1 (ko) 2021-01-29 2023-07-03 일리미스테라퓨틱스 주식회사 비염증성 식세포작용 유도 활성을 갖는 융합분자
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
CN114334076B (zh) * 2021-12-23 2025-03-21 华中科技大学 一种药食同源中药玉竹的重金属概率风险评估方法及系统
KR20250116724A (ko) * 2022-12-07 2025-08-01 알케맙 테라퓨틱스 엘티디 항-헌팅틴 항체

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
KR900700134A (ko) 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
CA2078689C (en) 1990-03-20 2003-02-11 Sherie L. Morrison Chimeric antibodies with receptor binding ligands in place of their constant region
EP1149913A1 (en) 1990-11-09 2001-10-31 GILLIES, Stephen D. Cytokine immunoconjugates
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
ES2088838T3 (es) 1992-11-13 2004-01-01 Idec Pharmaceuticals Corporation Secuencias kozak de consenso totalmente alteradas destinadas a la expresion en los mamiferos.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2116280A1 (en) 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US6255455B1 (en) * 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
JP4128227B2 (ja) 1997-03-14 2008-07-30 バイオジェン・アイデック・インコーポレイテッド 哺乳類細胞内の特定部位に相同組換えによって遺伝子を組み込む方法とそれを実施するためのベクター
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
ATE323288T1 (de) 1997-08-01 2006-04-15 Verfahren zur bestimmung von amyloid-ähnlichen fibrillen oder proteinaggregaten
WO2000030680A1 (en) 1998-11-23 2000-06-02 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
CA2378953A1 (en) * 1999-07-27 2001-02-01 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
ATE352040T1 (de) 2000-11-17 2007-02-15 Univ Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
CA2436092A1 (en) 2001-01-29 2002-08-08 Idec Pharmaceutical Corporation Modified antibodies and methods of use
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
ATE382704T1 (de) * 2001-02-15 2008-01-15 Univ Chicago Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
US7375194B2 (en) 2002-01-28 2008-05-20 California Institute Of Technology Antibodies that bind to an epitope on the Huntington's disease protein
CA2526893C (en) * 2003-05-14 2010-10-26 Japan Science And Technology Agency Inhibition of the expression of huntingtin gene
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
WO2005052002A2 (en) * 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
ES2439490T3 (es) * 2007-01-05 2014-01-23 University Of Zurich Anticuerpo anti-beta amiloide y usos del mismo
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US8022268B2 (en) * 2007-06-11 2011-09-20 The University Of Zurich Transgenic animal model for alzheimer's disease
WO2010069603A1 (en) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
NZ609984A (en) 2010-10-11 2015-05-29 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
CA2818781C (en) 2010-12-17 2019-10-08 Neurimmune Holding Ag Human anti-sod1 antibodies
US20140044644A1 (en) 2011-02-21 2014-02-13 University Of Zurich Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
US20140314784A1 (en) * 2011-07-20 2014-10-23 Medlmmune Limited Anti-cxcr4 antibodies and methods of use
EP2771359B1 (en) 2011-10-28 2021-05-19 Biogen International Neuroscience GmbH Tdp-43 specific binding molecules
EP3950712A1 (en) * 2013-05-29 2022-02-09 Vybion, Inc. Single chain intrabodies that alter huntingtin mutant degradation
RU2021100991A (ru) * 2014-07-10 2021-03-01 Аффирис Аг Вещества и способы для применения при предупреждении и/или лечении болезни гентингтона
DK3166660T3 (en) 2014-07-10 2018-02-05 Affiris Ag SUBSTANCES AND PROCEDURES FOR USE IN PREVENTION AND / OR TREATMENT OF HUNTINGTON'S DISEASE
EA201790165A1 (ru) 2014-07-29 2017-07-31 Нейриммьюн Холдинг Аг Происходящие от человека антитела к гентингтину (htt) и их применение

Also Published As

Publication number Publication date
US20200392217A1 (en) 2020-12-17
KR102643395B1 (ko) 2024-03-11
CA2954738A1 (en) 2016-02-04
EP3174898A2 (en) 2017-06-07
US20170166631A1 (en) 2017-06-15
AU2015295441A1 (en) 2017-02-02
MX2022003704A (es) 2022-04-26
JP7235939B2 (ja) 2023-03-09
CN113651887A (zh) 2021-11-16
JP7562168B2 (ja) 2024-10-07
US10556946B2 (en) 2020-02-11
AU2024200315A1 (en) 2024-02-08
MX391037B (es) 2025-03-21
WO2016016278A2 (en) 2016-02-04
AU2020217427A1 (en) 2020-09-03
US20220332808A1 (en) 2022-10-20
US11401325B2 (en) 2022-08-02
CN107074937B (zh) 2021-07-27
CN107074937A (zh) 2017-08-18
EP4406549A2 (en) 2024-07-31
EP4406549A3 (en) 2025-01-08
IL250180A0 (en) 2017-03-30
IL276721A (en) 2020-09-30
JP2017522886A (ja) 2017-08-17
WO2016016278A3 (en) 2016-03-24
EA201790165A1 (ru) 2017-07-31
JP2023052519A (ja) 2023-04-11
AU2015295441B2 (en) 2020-05-14
NZ728372A (en) 2021-11-26
AU2020217427B2 (en) 2023-10-19
JP2021003100A (ja) 2021-01-14
KR20170036785A (ko) 2017-04-03
MX2022003706A (es) 2022-04-26

Similar Documents

Publication Publication Date Title
MX2017001285A (es) Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
IL261163B (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
MX391159B (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
IL274891B (en) Preparations, kits and methods for inducing acquired cellular resistance using inducible stress proteins
PH12017500803A1 (en) Anti-pd-1 antibodies
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
BR112017014258A2 (pt) anticorpos anti-cd47 e usos dos mesmos
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
MX2015013202A (es) Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
EP4219744A3 (en) Methods of preparing nucleic acids for sequencing
MX375524B (es) Anticuerpos anti-axl.
EP3133071A4 (en) C-aryl indican derivative, and pharmaceutical composition thereof, preparation method therefor and uses thereof
WO2015001013A3 (en) Human anti-ifn-alpha antibodies
BR112017001417A2 (pt) variantes de proteína de ligação ao fator h e métodos para uso das mesmas
EA201790655A1 (ru) Новые активаторы растворимой гуанилатциклазы и их применение
SG10201806454RA (en) Anti-tenascin c antibodies and uses thereof
CY1120997T1 (el) Πρωτεϊνες συντηξης uti
ZA201801498B (en) An improved refolding process for antibody's fragments
HUE045393T2 (hu) TATK-CDKL5 fúziós fehérjék, készítmények, kiszerelések és alkalmazásuk
MX390967B (es) Composiciones y métodos para la modulación de la actividad at2r
NZ728041A (en) Substances and methods for the use in prevention and/or treatment in huntington’s disease